A de-escalated, chemotherapy-free neoadjuvant regimen of letrozole plus dual HER2 blockade showed promise in patients with HER2+/HR+ breast cancer who first achieved a molecular response to 2 weeks of letrozole.
More From BioPortfolio on "De-escalated, Chemo-Free Neoadjuvant Path Viable in HER2+/HR+ Breast Cancer"